Ascendis Pharma A/S (ASND)

Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	329.02	266.72	51.17	7.78	6.95	13.38
Revenue Growth (YoY)	322.18%	421.20%	557.93%	11.87%	-48.01%	26.41%
Cost of Revenue	47.34	44.4	12.14	3.52	0	0
Gross Profit	281.68	222.32	39.04	4.26	6.95	13.38
Selling, General & Admin	264.65	264.41	221.23	160.18	76.67	48.47
Research & Development	378.03	413.45	379.62	295.87	260.9	191.62
Operating Expenses	642.68	677.86	600.85	456.05	337.57	240.09
Operating Income	-361	-455.54	-561.81	-451.79	-330.62	-226.72
Interest Expense / Income	119.44	44.07	50.49	3.91	80.84	1.22
Other Expense / Income	12.62	-25.46	-34.48	-71.76	7.71	-9.69
Pretax Income	-493.06	-474.14	-577.82	-383.94	-419.17	-218.25
Income Tax	8.51	7.3	5.38	-0.37	-0.22	-0.23
Net Income	-501.57	-481.45	-583.19	-383.58	-418.96	-218.02
Shares Outstanding (Basic)	57	56	56	55	51	47
Shares Outstanding (Diluted)	57	56	56	55	51	47
Shares Change	1.41%	0.38%	2.37%	8.21%	8.84%	13.20%
EPS (Basic)	-8.87	-8.55	-10.40	-7.00	-8.28	-4.69
EPS (Diluted)	-8.87	-8.55	-10.40	-7.00	-8.28	-4.69
Free Cash Flow	-423.4	-469.75	-500.65	-441.88	-288.05	-181.1
Free Cash Flow Per Share	-7.44	-8.35	-8.93	-8.07	-5.69	-3.89
Gross Margin	85.61%	83.36%	76.28%	54.71%	100.00%	100.00%
Operating Margin	-109.72%	-170.79%	-1097.85%	-5808.59%	-4755.07%	-1695.10%
Profit Margin	-152.44%	-180.51%	-1139.63%	-4931.56%	-6025.53%	-1630.03%
Free Cash Flow Margin	-128.69%	-176.12%	-978.33%	-5681.19%	-4142.76%	-1353.98%
EBITDA	-354.77	-411.17	-509.37	-364.64	-328.88	-210.34
EBITDA Margin	-107.83%	-154.16%	-995.37%	-4688.12%	-4730.10%	-1572.64%
Depreciation & Amortization	18.84	18.91	17.96	15.39	9.45	6.69
EBIT	-373.62	-430.08	-527.33	-380.03	-338.33	-217.03
EBIT Margin	-113.55%	-161.25%	-1030.46%	-4886.00%	-4865.99%	-1622.65%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).